Company Profile

13therapeutics Inc (AKA: Gene Targeted Delivery Inc~Targeted Gene Delivery Inc)
Profile last edited on: 3/28/17      CAGE: 4FJ08      UEI: T5LFW55EF769

Business Identifier: Identify, characterize, and optimize anti-inflammatory peptide therapeutics
Year Founded
First Award
Latest Award
Program Status
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

4640 Sw Macadam Avenue Suite 200d
Portland, OR 97239
   (503) 525-4887
Location: Single
Congr. District: 03
County: Multnomah

Public Profile

Formerly known as Targeted Gene Delivery Inc, 13therapeutics is a research and drug development company identifying and characterizing novel anti-inflammatory peptide therapeutics for unmet medical needs with high commercial potential. The company has an innovative platform for discovering and enhancing peptides, derived from naturally occurring pathogens (e.g., bacteria, viruses, fungi), which modulate the human immune response. This platform has produced a portfolio of peptides with demonstrated immune-regulatory activity and with varying mechanisms of action. These peptides have potential application for treatment of both acute and chronic inflammatory diseases. Many of the company’s peptides are capable of multiple methods of delivery, have shown serum stability, and have other desired features clinical therapeutics. Target conditions include the treatment of acute inflammatory diseases such as Acute Otitis Media (AOM), Systemic Inflammation, Meningitis, Traumatic Brain Injury (TBI), Uveitis and Ischemia. We are also evaluating peptides in chronic models for Lupus, Rheumatoid Arthritis (RA), Multiple Sclerosis, Atherosclerosis, Crohn’s Disease and Psoriasis, among others. Using our evolution-based methodology, we envision rapid development across several disease sta

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
VC funded?
Privately Held
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2013 2 NIH $3,745,316
Project Title: Bacterial-Induced Sepsis: a New Treatment Strategy
2008 2 NIH $2,293,632
Project Title: New Treatment for Inflammation in Middle Ear Infections
2001 1 NIH $99,840
Project Title: New Therapy for Cystic Fibrosis DNA-Induced Inflammation
1997 1 NIH $99,687
Project Title: Gene Delivery by a Cell Surface Dna Binding Protein

Key People / Management

  Thomas H Bruggere -- Chairman and CEO

  Steven H Hefeneider -- President

  Stephen E Kurtz

  Sharon L McCoy -- Vice President of Product Development and Director of Research

  Louise S Merkens

Company News

There are no news available.